Back to all studies
CompletedNCT01485640

A Long-term, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study

This study is completed in France, in Canada, in Colombia, .... It is testing lurasidone for Schizophrenia; Bipolarity.

Schizophrenia, BipolarityDrug

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Lurasidone may be useful for people experiencing schizophrenia.

What would participation involve?

Participants may receive Lurasidone, attend study visits with the research team. The registry lists locations in Canada, in Colombia, and in Czechia.

Who is it mainly for?

This study appears to be mainly for people with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJune 2011
Recruitment status
Completed
Enrollment listed in the registry
162
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
France, Canada, Colombia, ...
Age range
Not clearly listed
Official registry ID
NCT01485640
Official title
A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT01485640. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Canada · 1 site
  • Okanagan Clinical Trials
    Kelowna, British Columbia
    Site status: Not listed — confirm with the team
Colombia · 3 sites
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA Investigations
    Barranquilla
    Site status: Not listed — confirm with the team
  • E.S.E. Hospital Mental de Antioquia
    Bello
    Site status: Not listed — confirm with the team
  • CISNE - UIC Campo Abierto
    Bogotá
    Site status: Not listed — confirm with the team
Czechia · 5 sites
  • Psychiatricka ambulance
    Brno-mesto
    Site status: Not listed — confirm with the team
  • Vojenska nemocnice Olomouc
    Olomouc
    Site status: Not listed — confirm with the team
  • Clintrial, s.r.o.
    Prague
    Site status: Not listed — confirm with the team
  • Psychiatry Trial s.r.o.
    Prague
    Site status: Not listed — confirm with the team
  • Medical Services Prague s.r.o.
    Prague
    Site status: Not listed — confirm with the team
France · 2 sites
  • Zans Ritter, Marcel
    Orvault
    Site status: Not listed — confirm with the team
  • Hôpital Chalucet, Centre hospitalier intercommunal de Toulon la Seyne sur mer (CHITS)
    Toulun
    Site status: Not listed — confirm with the team
India · 11 sites
  • Brain Mind Behavior Neuroscience Research Institute
    Visakhapatnam, Andh Prad
    Site status: Not listed — confirm with the team
  • Vijayawada Institute of Mental Health and Neurosciences
    Vijayawada, Andhra Pradesh
    Site status: Not listed — confirm with the team
  • Samvedna Hospitals
    Ahmedabad, Gujarat
    Site status: Not listed — confirm with the team
  • Seth K M School of P G Medicine & Research
    Ahmedabad, Gujarat
    Site status: Not listed — confirm with the team
  • Mental Health Treatment Rehabililitation Foundation Dept. of Psychiatry
    Ahmedabad, Gujarat
    Site status: Not listed — confirm with the team
  • Hatkesh Healthcare Foundation
    Jūnāgadh, Gujarat
    Site status: Not listed — confirm with the team
  • Brij Psychiatry Hospital & Muskaan Research Centre
    Vadodara, Gujarat
    Site status: Not listed — confirm with the team
  • Shanti Nursing Home
    Aurangabad, Maharashtra
    Site status: Not listed — confirm with the team
  • Dr. Tambi's Neuropsychiatry Center
    Jaipur, Rajaasthan
    Site status: Not listed — confirm with the team
  • R.K. Yadav Memorial Mental Health & De-Addiction Hospital Psychiatry
    Jaipur, Rajasthan
    Site status: Not listed — confirm with the team
  • Mahendru Psychiatric Centre
    Kanpur
    Site status: Not listed — confirm with the team
Lithuania · 3 sites
  • Neuromeda JSC
    Kaunas
    Site status: Not listed — confirm with the team
  • JSC Neuromeda
    Kaunas
    Site status: Not listed — confirm with the team
  • Seskines Outpatient Clinic, Public Institution
    Vilnius
    Site status: Not listed — confirm with the team
Romania · 2 sites
  • Spitalul Clinic Judetean de Urgenta Cluj
    Cluj-Napoca
    Site status: Not listed — confirm with the team
  • Spitalul Clinic de Neuropsihiatrie Craiova
    Craiova
    Site status: Not listed — confirm with the team
Russia · 4 sites
  • Regional Government Institution (RGI) 'Lipetsk Regional Psychoneurology Hospital'
    Lipetsk
    Site status: Not listed — confirm with the team
  • St. Petersburg State Budgetary Healthcare Institution 'City Psychoneurology Dispensary #7 (with In-Patient Department)', (SPb SBHI "CPNDD-7"), at Daycare Facility #1
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • St. Petersburg State Government Healthcare Institution "City Psychiatric Hospital #4" (St. Petersburg Insane Asylum Distributor)
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • St. Petersburg State Healthcare Institution (SPbSHI) "City Psychiatric Hospital #6"
    Saint Petersburg
    Site status: Not listed — confirm with the team
Serbia · 2 sites
  • Institute of Mental Health
    Belgrade
    Site status: Not listed — confirm with the team
  • Clinical Centre Nis, Clinic for mental health protection
    Niš
    Site status: Not listed — confirm with the team
Slovakia · 4 sites
  • Psychiatricka ambulancia Mentum s.r.o.
    Bratislava
    Site status: Not listed — confirm with the team
  • PsychoLine s.r.o. Psychiatricka ambulancia
    Rimavská Sobota
    Site status: Not listed — confirm with the team
  • Centrum zdravia R.B.K. s.r.o. Psychiatricka ambulancia
    Svidník
    Site status: Not listed — confirm with the team
  • Pro mente sana s.r.o. Psychiaricka ambulancia
    Trenčín
    Site status: Not listed — confirm with the team
South Africa · 3 sites
  • Dey Clinic
    Pretoria, Gauteng
    Site status: Not listed — confirm with the team
  • Cape Trial Centre
    Tygervalley, Western Cape
    Site status: Not listed — confirm with the team
  • Denmar Hospital Consulting Rooms
    Pretoria
    Site status: Not listed — confirm with the team
Ukraine · 6 sites
  • Kherson Regional Psychiatric Hospital
    Kherson, Vil Stepanivka
    Site status: Not listed — confirm with the team
  • Dnipropetrovsk Regional Clinical Hospital named Mechnikov
    Dnipropetrovsk
    Site status: Not listed — confirm with the team
  • Regional Clinical Psychiatric Hospital, Dept #11
    Donetsk
    Site status: Not listed — confirm with the team
  • Institute of Neurology, Psychiatry and Narcology, NAMS of Ukraine
    Khardov
    Site status: Not listed — confirm with the team
  • Crimean republican Clinical Psychiatric Hospital
    Simferopol
    Site status: Not listed — confirm with the team
  • Reg. Psych. Hosp.n.a.O.Yuschenko, Dept #21
    Vinnitsia
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Lurasidone. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Sumitomo Pharma America, Inc., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me